Development of drug-induced arthritis in a glioblastoma patient treated with pembrolizumab
Glioblastoma (GBM, WHO Grade IV) is the most aggressive form of primary brain cancer in adults, and as with other cancers, clinical investigations to use immunotherapy as a possible therapeutic option for GBM are underway. One form of immunotherapy is immune checkpoint inhibition that targets the pr...
Main Authors: | Casey B Brown, Katherine B Peters |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Glioma |
Subjects: | |
Online Access: | http://www.jglioma.com/article.asp?issn=2589-6113;year=2018;volume=1;issue=4;spage=142;epage=144;aulast=Brown |
Similar Items
-
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma
by: Natasha Lakin, et al.
Published: (2017-07-01) -
Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
by: Justin M. Hintze, et al.
Published: (2023-07-01) -
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
by: Antonio Omuro
Published: (2022-08-01) -
Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
by: Nicoletta F. Jaberg-Bentele, et al.
Published: (2017-03-01) -
Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
by: Giulio Rizzetto, et al.
Published: (2023-08-01)